Tonix Pharmaceuticals Holding Corp. [NASDAQ: TNXP] closed the trading session at $0.32 on 01/10/22. The day’s price range saw the stock hit a low of $0.315, while the highest price level was $0.3324. The company report on January 5, 2022 that Tonix Pharmaceuticals to Participate in Upcoming January Conferences.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate in the H.C. Wainwright BioConnect Conference and the Biotech Showcase 2022, both being held virtually.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The stocks have a year to date performance of -10.26 percent and weekly performance of -19.08 percent. The stock has been moved at -68.22 percent over the last six months. The stock has performed -19.85 percent around the most recent 30 days and changed -38.28 percent over the most recent 3-months.
If compared to the average trading volume of 16.84M shares, TNXP reached to a volume of 9288444 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Tonix Pharmaceuticals Holding Corp. [TNXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNXP shares is $2.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNXP stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Tonix Pharmaceuticals Holding Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 18, 2019. The new note on the price target was released on August 18, 2017, representing the official price target for Tonix Pharmaceuticals Holding Corp. stock. On February 17, 2016, analysts decreased their price target for TNXP shares from 18 to 10.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp. is set at 0.03 The Price to Book ratio for the last quarter was 0.58, with the Price to Cash per share for the same quarter was set at 0.37.
TNXP stock trade performance evaluation
Tonix Pharmaceuticals Holding Corp. [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.08. With this latest performance, TNXP shares dropped by -19.85% in over the last four-week period, additionally sinking by -68.22% over the last 6 months – not to mention a drop of -60.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 31.95, with the RSI for the last a single of trading hit 28.21, and the three-weeks RSI is set at 34.12 for Tonix Pharmaceuticals Holding Corp. [TNXP]. The present Moving Average for the last 50 days of trading for this stock 0.4534, while it was recorded at 0.3445 for the last single week of trading, and 0.7937 for the last 200 days.
Tonix Pharmaceuticals Holding Corp. [TNXP]: An insightful look at the core fundamentals
Return on Total Capital for TNXP is now -102.32, given the latest momentum, and Return on Invested Capital for the company is -103.21. Return on Equity for this stock declined to -103.98, with Return on Assets sitting at -89.52. When it comes to the capital structure of this company, Tonix Pharmaceuticals Holding Corp. [TNXP] has a Total Debt to Total Equity ratio set at 1.50. Additionally, TNXP Total Debt to Total Capital is recorded at 1.47, with Total Debt to Total Assets ending up at 1.34. Long-Term Debt to Equity for the company is recorded at 0.82, with the Long-Term Debt to Total Capital now at 0.80.
Reflecting on the efficiency of the workforce at the company, Tonix Pharmaceuticals Holding Corp. [TNXP] managed to generate an average of -$2,968,412 per employee.Tonix Pharmaceuticals Holding Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.20 and a Current Ratio set at 16.20.
Tonix Pharmaceuticals Holding Corp. [TNXP]: Insider Ownership positions
There are presently around $27 million, or 17.80% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: BLACKROCK INC. with ownership of 27,321,653, which is approximately 3.096% of the company’s market cap and around 0.06% of the total institutional ownership; VANGUARD GROUP INC, holding 16,006,620 shares of the stock with an approximate value of $5.14 million in TNXP stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $2.38 million in TNXP stock with ownership of nearly 34.438% of the company’s market capitalization.
Positions in Tonix Pharmaceuticals Holding Corp. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 44 institutional holders increased their position in Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] by around 14,474,367 shares. Additionally, 31 investors decreased positions by around 3,682,728 shares, while 25 investors held positions by with 66,931,325 shares. The mentioned changes placed institutional holdings at 85,088,420 shares, according to the latest SEC report filing. TNXP stock had 15 new institutional investments in for a total of 1,584,709 shares, while 12 institutional investors sold positions of 819,361 shares during the same period.